AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 166929 — intervention group
Group type: COMPARATOR
Intervention: Parainfluenza virus only (control)
Number of subjects: 10
Study 29164609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral and mindfulness-based group sleep intervention ('Sleep SENSE')
Number of subjects: 123
Study 29164609 — intervention group
Group type: COMPARATOR
Intervention: Active control 'study skills' intervention ('Study SENSE')
Number of subjects: 123
Study 27060930 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily
Number of subjects: 368
Study 27060930 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 368
Study 24720526 — intervention group
Group type: COMPARATOR
Intervention: Zumba
Number of subjects: 118
Study 24720526 — intervention group
Group type: COMPARATOR
Intervention: Soccer
Number of subjects: 118
Study 24720526 — intervention group
Group type: COMPARATOR
Intervention: Both intervention groups
Number of subjects: 118
Study 23278906 — intervention group
Group type: COMPARATOR
Intervention: Group C: 1 ml·kg(‐1) of 0.25% ropivacaine injected after needle insertion into the sacral canal
Number of subjects: 140
Study 23278906 — intervention group
Group type: EXPERIMENTAL
Intervention: Group H: 1 ml·kg(‐1) of 0.25% ropivacaine injected after needle pierced the sacrococcygeal ligament under ultrasound guidance
Number of subjects: 140
Study 19378318 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD group
Number of subjects: 432
Study 19378318 — intervention group
Group type: COMPARATOR
Intervention: LNCG
Number of subjects: 432
Study 18792885 — intervention group
Group type: EXPERIMENTAL
Intervention: High-heat-processed meal (HHPM)
Number of subjects: 20
Study 18792885 — intervention group
Group type: COMPARATOR
Intervention: Low-heat-processed meal (LHPM)
Number of subjects: 20
Study 17323720 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 0
Study 17323720 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 17323720 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint
Number of subjects: 0
Study 17323720 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 0
Study 14638349 — intervention group
Group type: EXPERIMENTAL
Intervention: MTZ trial
Number of subjects: 0
Study 14638349 — intervention group
Group type: EXPERIMENTAL
Intervention: CIP trial
Number of subjects: 0
Study 14638349 — intervention group
Group type: EXPERIMENTAL
Intervention: MTZ-then-CIP trial
Number of subjects: 0
Study 14638349 — intervention group
Group type: EXPERIMENTAL
Intervention: CIP-then-MTZ trial
Number of subjects: 0
Study 14638349 — intervention group
Group type: EXPERIMENTAL
Intervention: Pouch endoscopy with biopsy
Number of subjects: 0
Study 14638349 — intervention group
Group type: EXPERIMENTAL
Intervention: Pouch endoscopy without biopsy
Number of subjects: 0
Study 11127486 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 0
Study 11127486 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 9290118 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation at 30 mg/day
Number of subjects: 12
Study 9290118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8365385 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid diet
Number of subjects: 55
Study 8365385 — intervention group
Group type: EXPERIMENTAL
Intervention: Stearic acid diet
Number of subjects: 55
Study 8365385 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans fatty acid diet
Number of subjects: 55
Study 3602015 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol/diuretic (5 mg amiloride plus 50 mg hydrochlorothiazide once daily)
Number of subjects: 98
Study 3602015 — intervention group
Group type: COMPARATOR
Intervention: Atenolol/nifedipine (20 mg nifedipine twice daily)
Number of subjects: 98
Study 3602015 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol/diuretic
Number of subjects: 98
Study 3602015 — intervention group
Group type: COMPARATOR
Intervention: Atenolol/nifedipine
Number of subjects: 98
Study 3602015 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 98
Study 2599441 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth‐II (BII) anastomosis (n = 9)
Number of subjects: 17
Study 2599441 — intervention group
Group type: COMPARATOR
Intervention: Roux‐en‐Y (RY) anastomosis (n = 8)
Number of subjects: 17
Study 2599441 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth‐II (BII) anastomosis (n = 4, cleared from Campylobacter pylori)
Number of subjects: 17
Study 31150502 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 23
Study 31150502 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Number of subjects: 23
Study 31150502 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 23
Study 31150502 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants and Oxytocin
Number of subjects: 23
Study 26875155 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program consisting of six group sessions combined with an eHealth module
Number of subjects: 31
Study 26875155 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program
Number of subjects: 31
Study 25462913 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise on a treadmill at moderate intensity (60‐70% VO2max; AER) for 30 min
Number of subjects: 2
Study 25462913 — intervention group
Group type: COMPARATOR
Intervention: Placebo exercise (PLAC) for 30 min
Number of subjects: 2
Study 23601522 — intervention group
Group type: EXPERIMENTAL
Intervention: Delimiting preventive medicine treatment (Group 1)
Number of subjects: 12860
Study 23601522 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine medicine treatment (Group 2)
Number of subjects: 12860
Study 23601522 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Non-intervention group)
Number of subjects: 12860
Study 21908162 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual pressure support (PS) reduction without an initial spontaneous breathing trial (SBT)
Number of subjects: 120
Study 21908162 — intervention group
Group type: COMPARATOR
Intervention: PS-supported SBT (PS 7cm H(2)O)
Number of subjects: 120
Study 21908162 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual pressure support (PS) reduction without an initial SBT
Number of subjects: 120
Study 21908162 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 19920273 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 0
Study 19920273 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical breast examination
Number of subjects: 0
Study 19920273 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self-examination
Number of subjects: 0
Study 17120960 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (12 mg, 200 microg/kg bodyweight)
Number of subjects: 30
Study 17120960 — intervention group
Group type: COMPARATOR
Intervention: Placebo (40 mg of vitamin B1)
Number of subjects: 30
Study 17120960 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 30
Study 17120960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12028093 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy with laser aiming guide
Number of subjects: 880
Study 12028093 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy without aiming guide
Number of subjects: 880
Study 10349922 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml lidocaine 1.5% plus 15 microg epinephrine (1:200,000) i.v. at sevoflurane 0.5%
Number of subjects: 120
Study 10349922 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml lidocaine 1.5% plus 15 microg epinephrine (1:200,000) i.v. at sevoflurane 1%
Number of subjects: 120
Study 10349922 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml lidocaine 1.5% plus 15 microg epinephrine (1:200,000) i.v. at sevoflurane 2%
Number of subjects: 120
Study 10349922 — intervention group
Group type: COMPARATOR
Intervention: 3 ml normal saline at sevoflurane 0.5%
Number of subjects: 120
Study 10349922 — intervention group
Group type: COMPARATOR
Intervention: 3 ml normal saline at sevoflurane 1%
Number of subjects: 120
Study 10349922 — intervention group
Group type: COMPARATOR
Intervention: 3 ml normal saline at sevoflurane 2%
Number of subjects: 120
Study 10349922 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml lidocaine 1.5% plus 15 microg epinephrine (1:200,000) i.v. (all concentrations)
Number of subjects: 120
Study 10349922 — intervention group
Group type: COMPARATOR
Intervention: 3 ml normal saline (all concentrations)
Number of subjects: 120
Study 8535466 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonophoresis with .33% dexamethasone
Number of subjects: 28
Study 8535466 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound with .33% dexamethasone
Number of subjects: 28
Study 8535466 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 28
Study 8535466 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 28
Study 1685691 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine (0.5 mg/ml)
Number of subjects: 0
Study 1685691 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate (20 mg/ml)
Number of subjects: 0
Study 1685691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1685691 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine
Number of subjects: 0
Study 1685691 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate
Number of subjects: 0
Study 1685691 — intervention group
Group type: COMPARATOR
Intervention: Levocabastine and Sodium cromoglycate
Number of subjects: 0
Study 7003383 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 33
Study 7003383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 31975537 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-plasty (ZP)
Number of subjects: 67
Study 31975537 — intervention group
Group type: COMPARATOR
Intervention: Conventional simple excision (SE)
Number of subjects: 67
Study 29236527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 122
Study 29236527 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 122
Study 28078825 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 70% + unfractionated heparin 2000 U/mL
Number of subjects: 103
Study 28078825 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin 2000 U/mL
Number of subjects: 103
Study 26603516 — intervention group
Group type: EXPERIMENTAL
Intervention: Good Neighbour Partnership (GNP) in addition to standard care
Number of subjects: 80
Study 26603516 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 80
Study 23623156 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Hz rTMS (500 pulses/session)
Number of subjects: 70
Study 23623156 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 70
Study 21530557 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (1mg)
Number of subjects: 8
Study 21530557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 18382904 — intervention group
Group type: EXPERIMENTAL
Intervention: leuprorelin + hMG
Number of subjects: 0
Study 18382904 — intervention group
Group type: COMPARATOR
Intervention: ganirelix + rFSH
Number of subjects: 0
Study 16972708 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive designs in phase III clinical trials
Number of subjects: 0
Study 12595492 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 073
Number of subjects: 71
Study 12595492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 11042235 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17‐beta‐estradiol
Number of subjects: 10
Study 11042235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9038437 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapleson A mode of the Carden system with a mean fresh gas flow of 2.61 min‐1
Number of subjects: 77
Study 9038437 — intervention group
Group type: COMPARATOR
Intervention: Circle absorber mode with a mean fresh gas flow of 1.21 min‐1
Number of subjects: 77
Study 9038437 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow anaesthesia
Number of subjects: 77
Study 1732265 — intervention group
Group type: EXPERIMENTAL
Intervention: A-V Impulse System (mechanical prophylaxis for venous thrombo-embolism)
Number of subjects: 60
Study 1732265 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 60
Study 6542834 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (250 ml, 7%)
Number of subjects: 8
Study 6542834 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (250 ml, 7%)
Number of subjects: 8
Study 6542834 — intervention group
Group type: COMPARATOR
Intervention: Water (250 ml)
Number of subjects: 8
Study 6542834 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (1.3 +/- 0.4 mmol kg d.w.‐1 min‐1)
Number of subjects: 8
Study 6542834 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (2.1 +/- 0.5 mmol kg d.w.‐1 min‐1)
Number of subjects: 8
Study 6542834 — intervention group
Group type: COMPARATOR
Intervention: Water (2.3 +/- 0.5 mmol kg d.w.‐1 min‐1)
Number of subjects: 8
Study 30606259 — intervention group
Group type: EXPERIMENTAL
Intervention: Total CTC count cut-off value of 9.5
Number of subjects: 108
Study 30606259 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of mesenchymal CTCs cut-off value of 10.7%
Number of subjects: 108
Study 30606259 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined criteria of total CTC count ≥10/5 mL and proportion of mesenchymal CTCs >10.7%
Number of subjects: 108
Study 30606259 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on combined criteria and clinicopathological characteristics
Number of subjects: 108
Study 29445928 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib and trastuzumab (6 weeks) followed by lapatinib and trastuzumab plus weekly paclitaxel (12 weeks) with prolonged anti-HER2 therapy (18 weeks)
Number of subjects: 215
Study 29445928 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib and trastuzumab (6 weeks) followed by lapatinib and trastuzumab plus weekly paclitaxel (12 weeks) with standard anti-HER2 therapy (6 weeks)
Number of subjects: 215
Study 29445928 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib and trastuzumab (6 weeks) followed by lapatinib and trastuzumab plus weekly paclitaxel (12 weeks) with endocrine therapy
Number of subjects: 215
Study 29445928 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib and trastuzumab (6 weeks) followed by lapatinib and trastuzumab plus weekly paclitaxel (12 weeks) without endocrine therapy
Number of subjects: 215
Study 29445928 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged anti-HER2 therapy
Number of subjects: 215
Study 27567886 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine ≤8 mg/24 h for early PD (HY 1 and 2)
Number of subjects: 2057
Study 27567886 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine ≤16 mg/24 h for advanced PD (HY 3 and 4)
Number of subjects: 2057
Study 27567886 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 2057
Study 27567886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2057
Study 26334249 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose TIV (0.5 mL)
Number of subjects: 243
Study 26334249 — intervention group
Group type: COMPARATOR
Intervention: Half-dose TIV (0.25 mL)
Number of subjects: 243
Study 23069270 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice (330 ml/d)
Number of subjects: 106
Study 23069270 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 106
Study 20497416 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine-ER + α-blocker
Number of subjects: 645
Study 20497416 — intervention group
Group type: COMPARATOR
Intervention: placebo + α-blocker
Number of subjects: 645
Study 18718007 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mcg sublingual misoprostol
Number of subjects: 61
Study 18718007 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 61
Study 16644320 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including provider education, patient education materials, feedback on beta-blocker use, and access to telephone consultation with an HF expert.
Number of subjects: 2631
Study 16644320 — intervention group
Group type: COMPARATOR
Intervention: Control practices (no multifaceted intervention).
Number of subjects: 2631
Study 14668172 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of caffeine
Number of subjects: 13
Study 14668172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 10824772 — intervention group
Group type: EXPERIMENTAL
Intervention: New Pathway Program (NP)
Number of subjects: 100
Study 10824772 — intervention group
Group type: COMPARATOR
Intervention: Traditional curriculum
Number of subjects: 100
Study 9352865 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic stent shunting (TIPS)
Number of subjects: 83
Study 9352865 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy plus propranolol (ES)
Number of subjects: 83
Study 1490436 — intervention group
Group type: EXPERIMENTAL
Intervention: BPAA gel
Number of subjects: 0
Study 1490436 — intervention group
Group type: COMPARATOR
Intervention: diclofenac emulgel
Number of subjects: 0
Study 3916457 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 22
Study 3916457 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin
Number of subjects: 22
Study 31053084 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin in ARDS patients
Number of subjects: 0
Study 31053084 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin in sepsis trials
Number of subjects: 0
Study 31053084 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone in sepsis trials
Number of subjects: 0
Study 31053084 — intervention group
Group type: COMPARATOR
Intervention: Levosimendan in sepsis trials
Number of subjects: 0
Study 29105521 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized parent history-taking training
Number of subjects: 0
Study 27427502 — intervention group
Group type: EXPERIMENTAL
Intervention: Hilotherapy system
Number of subjects: 40
Study 27427502 — intervention group
Group type: COMPARATOR
Intervention: Ice bag (cryotherapy)
Number of subjects: 40
Study 25147328 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 4731
Study 25147328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4731
Study 25147328 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d (in subgroup with diabetes mellitus)
Number of subjects: 4731
Study 25147328 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in subgroup with diabetes mellitus)
Number of subjects: 4731
Study 22251025 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care enhanced by provider education on depression evaluation and management
Number of subjects: 344
Study 22251025 — intervention group
Group type: COMPARATOR
Intervention: Quality improvement (QI) intervention designed to improve access to antidepressant medications and/or cognitive behavior therapy
Number of subjects: 344
Study 19744750 — intervention group
Group type: EXPERIMENTAL
Intervention: Chyme reinfusion (CR)
Number of subjects: 26
Study 18656720 — intervention group
Group type: EXPERIMENTAL
Intervention: BiClamp forceps tonsillectomy (BT)
Number of subjects: 0
Study 18656720 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery tonsillectomy (ET)
Number of subjects: 0
Study 15812374 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuation-corrected SPECT
Number of subjects: 116
Study 15812374 — intervention group
Group type: COMPARATOR
Intervention: Non-attenuation-corrected SPECT
Number of subjects: 116
Study 15812374 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuation-corrected SPECT (BMI <30)
Number of subjects: 116
Study 15812374 — intervention group
Group type: COMPARATOR
Intervention: Non-attenuation-corrected SPECT (BMI <30)
Number of subjects: 116
Study 15812374 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuation-corrected SPECT (BMI >=30)
Number of subjects: 116
Study 15812374 — intervention group
Group type: COMPARATOR
Intervention: Non-attenuation-corrected SPECT (BMI >=30)
Number of subjects: 116
Study 12587107 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) infusions
Number of subjects: 0
Study 12587107 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 10545433 — intervention group
Group type: EXPERIMENTAL
Intervention: Single premature extrastimuli (S(2))
Number of subjects: 30
Study 7994860 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular pacing alone (simulating VT)
Number of subjects: 21
Study 7994860 — intervention group
Group type: COMPARATOR
Intervention: Atrioventricular sequential pacing (simulating supraventricular tachycardia or VT with intact VA conduction)
Number of subjects: 21
Study 7994860 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial pulse
Number of subjects: 21
Study 7994860 — intervention group
Group type: EXPERIMENTAL
Intervention: Jugular venous pulse (JVP)
Number of subjects: 21
Study 7994860 — intervention group
Group type: EXPERIMENTAL
Intervention: First heart sound
Number of subjects: 21
Study 2471025 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine-pranobex (INPX) 1000 mg every 6 hours for 3 months
Number of subjects: 553
Study 2471025 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine-pranobex (INPX)
Number of subjects: 553
Study 2471025 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 553
Study 169536 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4-10 (30 mg/s.c.)
Number of subjects: 18
Study 169536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 169536 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4-10
Number of subjects: 18